Research results from Virginia Commonwealth University, Department of Biomedical Engineering update understanding of nanotechnology
2007 NOV 19 -- Investigators publish new data in the report 'Stealth dendrimers for antiarrhythmic quinidine delivery.' According to recent research from the United States, "Dendrimers have been attracting growing attention because of their unique well-defined globular nanoscale architecture and numerous functional groups on the surface. Attachment of PEG to the dendrimer generates stealth dendrimers, which have promising structural advantages for drug delivery." "In this study, synthetic methods were explored to deliver antiarrhythmic quinidine by stealth dendrimers. In particular, quinidine was covalently attached to anionic G2.5 and cationic G3.0 polyamidoamine (PAMAM) dendrimers via a glycine spacer, respectively. The resulting quinidine-PAMAM-PEG conjugates were characterized and confirmed by FT-IR and (1)H-NMR," wrote H. Yang and colleagues, Virginia Commonwealth University, Department of Biomedical Engineering. The researchers concluded: "In vitro hydrolysis was carried out in pH 7.4 PBS buffer at 37 degrees C to confirm the bioavailability of the conjugated quinidine." Yang and colleagues published their study in the Journal of Materials Science (Stealth dendrimers for antiarrhythmic quinidine delivery. Journal of Materials Science, 2007;18(10):2061-5). For additional information, contact H. Yang, Virginia Commonwealth University, Dept. of Biomedical Engineering, Richmond, VA 23284-3067 USA.. Publisher contact information for the Journal of Materials Science is: Kluwer Academic Publ, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. Keywords: United States, Richmond, Antiarrhythmic, Antimalarial, Nanotechnology, Quinidine, Therapy, Treatment. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
